A wireless electronic device for treating diabetes and obesity without drugs has been tested in mice

The fact that this work is to be published in Science made a positive impression on me, and I approached it with very high expectations—especially regarding its potential for clinical application. Indeed, I find it an ingenious and well-developed piece of work as a proof of concept. The authors carefully examine how the device functions, demonstrating that it successfully reduces both glucose levels and body weight in mice with diabetes and obesity. The implant uses electricity to convert a portion of the glucose into a substance that the body can then excrete through urine; connected to a sensor, it adjusts its activity based on the prevailing sugar levels. There is prior research in this area, including a study by the same group published in 2023 that combined glucose consumption with insulin release. The current contribution lies in the ability to electrically control this conversion process without the need for insulin or other glucose-lowering drugs.

That said, enthusiasm should be tempered with caution. The study was conducted on small groups of mice with a specific genetic alteration, which does not capture the full diversity of diabetes and obesity as they manifest in humans. The treatment was evaluated over six weeks, and the fully automated system over twelve days. It remains to be seen whether the implant can function safely over a long period, and how it might perform in cases where kidney function—responsible for eliminating the reaction byproduct—is compromised. While the absence of adverse effects in these experiments is promising, it does not yet guarantee safety in humans. In the context of diabetes and obesity, success must also be measured by a reduction in complications and an improved quality of life. It is an intriguing approach, though my initial expectations regarding its clinical application must, for now, await the next stages of development.

In my view, this article is highly innovative; it introduces a methodology for regulating blood glucose levels that differs significantly from existing approaches, as it does not rely on pharmacological treatments. It provides foundational evidence that controlled electrocatalysis leads to the formation of gluconate under specific conditions. From a technical standpoint, the methodology is compelling and highly applicable, featuring a well-designed implantable device with a closed-loop control system. However, given the novelty of this technology, it naturally raises reasonable questions regarding its practical application and potential side effects from a purely biological perspective.

The article builds upon existing biochemical knowledge concerning the products and outcomes of the electrochemical catalysis of glucose. Yet, it fails to address the potential changes that might arise from altering the chemical reaction environment—a critical consideration, given that the human body comprises numerous distinct microsystems. In this context, beyond gluconate, other products and byproducts could be generated—some of which, such as free fatty acids and ketone bodies, are mentioned in the article itself.

This work serves as a promising starting point for gaining a deeper understanding of how such devices might eventually become part of our therapeutic arsenal for conditions like diabetes and obesity.

Regarding the device itself, I see no inherent limitations; the approach is both novel and promising, demonstrating how technological advancement can significantly improve the quality of life for patients. Nevertheless, the potential outcomes of its use raise certain concerns that act as limitations. Broadly speaking, the article does not clarify whether the formation of other compounds resulting from electrocatalysis has been ruled out. Furthermore, it remains unclear whether variations in factors such as pH, exposure duration, or tissue location could alter the described conditions, potentially leading to harmful effects. Additionally, the study does not explore whether glucose byproducts—such as free fatty acids and ketone bodies—might have long-term metabolic consequences. 

I find this work very interesting, especially given how novel the idea is. The researchers have developed a small device that is implanted under the skin and is capable of removing excess glucose from the blood via an electrical mechanism, without the need for medication.

Most notably, in the mice studied, they not only succeeded in controlling glucose levels but also achieved a reduction in body weight—by as much as 10%—with no significant adverse effects observed during the follow-up period.

I believe its primary strength lies in the fact that it proposes an entirely different way of treating diabetes and obesity, using technology to act directly on excess glucose.

That said, we must exercise caution. We are talking about animal studies, and many questions remain to be answered. For instance, would it work the same way in humans? Would it be safe in the long term? And what might be the consequences of continuously removing glucose from the body? Furthermore, diabetes and obesity are far more complex conditions than a simple excess of sugar in the blood.

In any case, I believe this is a very promising line of research. It does not mean that current treatments will be replaced in the near term, but it does demonstrate that we can explore therapeutic strategies that, until recently, might have seemed like science fiction.